Against expectations, France has resisted imposing a nationwide lockdown, choosing to introduce new Covid-19 border restrictions instead. Under the new restrictions, all non-essential travel from outside the EU has been banned and testing requirements for travellers from within the EU have been tightened. French Prime Minister Jean Castex said France's night curfew would also be more tightly enforced and large shopping centres would close. It had been expected that French President Emmanuel Macron would impose a third national lockdown to contain Covid-19. However, the French premiere opted to tighten existing restrictions on travel and shopping instead. The move sees France following a different path than its two biggest neighbours Britain and Germany, at a time when the more contagious UK variant of the disease is spreading rapidly across Europe. [Related reading: Moderna says its vaccine will work against new COVID variants] "Everything suggests that a new wave could occur because of the variant, but perhaps we can avoid it thanks to the measures that we decided early and that the French people are respecting," Health Minister Olivier Veran told the Journal du Dimanche (JDD) newspaper on Sunday. Despite the news of tighter border restrictions, France Surgery’s proprietary telehealth platforms remain open and accessible to all of our international clients, one of the main benefits of remote healthcare.
With reports emerging that several different COVID variants are now circulating around the world, Moderna has released a statement saying it believes its vaccine protects against at least two of the new strains. Moderna Inc said on Monday it believes its COVID-19 vaccine protects against both new variants found in Britain and South Africa. However, the American pharmaceutical and biotechnology company also said it will test a separate booster shot aimed at the South African variant after concluding the antibody response could be diminished. The company said in a press release that it found no reduction in the antibody response against the variant found in Britain. Against the South African variant, Moderna said it found a reduced response but still believed its two-dose regimen would provide protection. The emergence of new COVID variants in Britain, South Africa and Brazil has created some concern that mutations in the virus may make vaccines less effective. Moderna’s announcement will serve to alleviate some of that concern, but the proof will be in the infection numbers going forward. Moderna shares rose nearly 10% off the back of the news during Monday trading. Moderna said it plans to publish data from its tests against the variants on the website bioRxiv.
Despite more than 40 countries recently closing their borders to travellers from the UK, cases of the new variant Covid-19 virus have been confirmed in several European countries, including Spain, Sweden and Switzerland. All of the confirmed cases were linked to people who had arrived from the UK. The revelations take the total number of new countries impacted by the new variant to 15, with South Korea the latest nation to announce a confirmed case. According to Reuters, the Korea Disease Control and Prevention Agency (KDCPA) found traces of the United Kingdom (UK) variant in three individuals from London who entered South Korea on December 22. Meanwhile, both Canada and Japan have also announced that they have found traces of the new Covid-19 strain in their countries. What is most alarming about Canada’s announcement is that the individual in which the new variant was discovered has no known travel history and exposure or high-risk contact. Scientists from the Independent Sage group have urged all regions of England to be placed under tier 4 restrictions, meaning that non-essential shops, hairdressers, and leisure and entertainment venues cannot operate. With evidence emerging that the new variant appears to be particularly infectious among children, teaching unions have urged for schools to remain closed. Speaking about the new variant, Paul Hunter, professor in medicine at the University of East Anglia, said: “If this new variant is behind the increase in this age group, then that is a big worry.”